Table 5.
The univariate and multivariate analyses of overall survival.
| Univariate analyses Multivariate analyses | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Median OS (95% CI) | HR(95% CI) | P value | β | S.E. | Wald | df | HR(95% CI) | P value | |
| Gender(Female vs. Male) | 2.046(0.909, 4.604) | 0.084 | 0.275 | 0.439 | 0.394 | 1 | 1.317(0.557, 3.112) | 0.530 | |
| Male | *26.54(22.61-30.47) | ||||||||
| Female | 14.67(7.628-21.70) | ||||||||
| Age | 1.368(0.574, 3.260) | 0.480 | |||||||
| <65 | *26.34(20.43-32.24) | ||||||||
| ≥65 | * 24.11(19.73-28.48) | ||||||||
| Smoking history | 1.312(0.582, 2.956) | 0.512 | |||||||
| Non-smokers | 21.00(13.91-28.01) | ||||||||
| Smokers | *24.88(20.96-28.80) | ||||||||
| Histology | 1.307(0.567, 3.012) | 0.530 | |||||||
| ADC | *24.01(19.57-28.45) | ||||||||
| Non-ADC | *25.94(20.76-31.13) | ||||||||
| Histology | 1.186(0.497, 2.826) | 0.701 | |||||||
| SCC | *25.49(19.76-31.21) | ||||||||
| Non-SCC | *24.44(20.21-28.68) | ||||||||
| Stage | 1.736(0.596, 5.057) | 0.312 | |||||||
| III | *23.30(18.82-27.79) | ||||||||
| IV | * 23.96(19.91-27.99) | ||||||||
| Distant metastases | 2.037(0.700, 5.928) | 0.192 | 0.392 | 0.576 | 0.465 | 1 | 1.481(0.479, 4.577) | 0.495 | |
| Yes | * 23.56(19.44-27.68) | ||||||||
| No | * 23.77(19.62-27.91) | ||||||||
| Tumor size | 1.054(0.487, 2.285) | 0.893 | |||||||
| <3 cm | * 24.74(19.94-29.54) | ||||||||
| ≥3 cm | * 25.07(19.94-30.19) | ||||||||
| Camrelizumab treatment | 1.184(0.546, 2.565) | 0.669 | |||||||
| Monotherapy | * 24.93(20.20-29.66) | ||||||||
| Combination | * 24.15(18.74-29.57) | ||||||||
| Treatment interval | 1.096(0.502, 2.389) | 0.818 | |||||||
| 3 weeks | * 25.32(20.20-30.43) | ||||||||
| 2 weeks | * 24.48(19.67-29.28) | ||||||||
| Response to camrelizumab | 15.10(6.830, 33.38) | 0.0003 | 2.651 | 1.026 | 6.674 | 1 | 14.17(1.896, 105.8) | 0.010 | |
| CR+PR | *not reached | ||||||||
| SD+PD | *19.40(11.17-27.63) | ||||||||
| Response to camrelizumab | 9.850(1.035, 93.78) | <0.0001 | |||||||
| CR+PR+SD | * not reached | ||||||||
| PD | *10.3(3.454-24.15) | ||||||||
*Mean overall survival. ADC, Adenocarcimona; CR, complete response; ECOG:Eastern Cooperation of Oncology Group;Non-ADC, Non-adenocarcinoma; Non-SCC: Non-squamous lung cancer; PD, Progression disease; PR, Partial response; SCC: Squamous cell lung cancer; SD, Stable disease.